Enhanced Pain Relief and Function Improvement in Children with Osgood-Schlatter Disease: Leukocyte-Rich Platelet-Rich Plasma (LR-PRP) as a Complementary Treatment to Standard Conservative Therapy

Tomasz Guszczyn; Monika Kulesza; Aleksandra Kicman; Joanna Motyka; Sławomir Ławicki

doi:10.12659/MSM.941523

18 December 2023: Clinical Research

Enhanced Pain Relief and Function Improvement in Children with Osgood-Schlatter Disease: Leukocyte-Rich Platelet-Rich Plasma (LR-PRP) as a Complementary Treatment to Standard Conservative Therapy

Tomasz Guszczyn ^1ABDEF* , Monika Kulesza ^2BCDEF , Aleksandra Kicman ^3CF , Joanna Motyka ^2CF , Sławomir Ławicki ^2AEG

DOI: 10.12659/MSM.941523

Med Sci Monit 2023; 29:e941523

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Table 2 The comparison of the results of the knee pain and function scales (VAS, Lysholm, Tegner, and KOOS) before and after PRP (Platelet-Rich Plasma) injection.

		Median	Mean±SD	Min–max	p* (before injection vs after injection)
VAS scale	Pre-injection	7	6.88±1.48	1–10	p
VAS scale	Post-injection	1	1.49±1.73	0–7	p
TEGNER scale	Pre-injection	5	5.58±1.35	4–9	p
TEGNER scale	Post-injection	6	6.25±1.64	4–10	p
LYSHOLM scale	Pre-injection	84	84.20±4.94	69–98	p
LYSHOLM scale	Post-injection	95	93.57±4.77	81–100	p
KOOS scale	Pre-injection	83	83.17±5.93	60–92	p
KOOS scale	Post-injection	97	94.33±6.13	75–100	p

Back to the Article

Enhanced Pain Relief and Function Improvement in Children with Osgood-Schlatter Disease: Leukocyte-Rich Platelet-Rich Plasma (LR-PRP) as a Complementary Treatment to Standard Conservative Therapy

Your Privacy